Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
113.16
-0.84 (-0.74%)
At close: Mar 28, 2025, 4:00 PM
112.00
-1.16 (-1.03%)
Pre-market: Mar 31, 2025, 8:51 AM EDT
Neurocrine Biosciences Market Cap
Neurocrine Biosciences has a market cap or net worth of $11.28 billion as of March 31, 2025. Its market cap has decreased by -20.04% in one year.
Market Cap
11.28B
Enterprise Value
10.70B
1-Year Change
-20.04%
Ranking
Category
Stock Price
$113.16
Market Cap Chart
Since December 1, 1998, Neurocrine Biosciences's market cap has increased from $124.10M to $11.28B, an increase of 8,991.42%. That is a compound annual growth rate of 18.68%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Mar 28, 2025 | 11.28B | -18.36% |
Dec 31, 2024 | 13.82B | 6.76% |
Dec 29, 2023 | 12.95B | 12.74% |
Dec 30, 2022 | 11.48B | 42.11% |
Dec 31, 2021 | 8.08B | -9.78% |
Dec 31, 2020 | 8.96B | -9.54% |
Dec 31, 2019 | 9.90B | 52.87% |
Dec 31, 2018 | 6.48B | -5.69% |
Dec 29, 2017 | 6.87B | 104.24% |
Dec 30, 2016 | 3.36B | -31.05% |
Dec 31, 2015 | 4.88B | 187.17% |
Dec 31, 2014 | 1.70B | 169.95% |
Dec 31, 2013 | 629.00M | 26.66% |
Dec 31, 2012 | 496.60M | 5.73% |
Dec 30, 2011 | 469.70M | 12.07% |
Dec 31, 2010 | 419.10M | 293.15% |
Dec 31, 2009 | 106.60M | -13.68% |
Dec 31, 2008 | 123.50M | -28.41% |
Dec 31, 2007 | 172.50M | -56.31% |
Dec 29, 2006 | 394.80M | -82.96% |
Dec 30, 2005 | 2.32B | 28.86% |
Dec 31, 2004 | 1.80B | -6.54% |
Dec 31, 2003 | 1.92B | 37.67% |
Dec 31, 2002 | 1.40B | 3.88% |
Dec 31, 2001 | 1.35B | 84.02% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 738.61B |
UnitedHealth Group | 472.03B |
Johnson & Johnson | 394.52B |
AbbVie | 363.15B |
Novo Nordisk | 305.46B |
AstraZeneca | 229.16B |
Abbott Laboratories | 226.88B |
Merck & Co. | 225.40B |